NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Monday reported a loss of $40.5 million in its second quarter.

On a per-share basis, the New York-based company said it had a loss of 30 cents.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 49 cents per share.

The biopharmaceutical company posted revenue of $594,000 in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $86,000.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TGTX at https://www.zacks.com/ap/TGTX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News